Please use this identifier to cite or link to this item:
|Efficacy and safety of direct-acting antiviral agents when combined with secukinumab
|Martínez Santana, Virginia
Rodríguez Murphy, Esther
Smithson Amat, Alejandro
Miserachs Aranda, Nuria
Río-Gil, Ruben del
Torre Lloverás, Inmaculada
Interaccions dels medicaments
|Background: The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown. Case report: We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis. Conclusion: This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.
|Reproducció del document publicat a: https://doi.org/10.1136/ejhpharm-2017-001212
|It is part of:
|European Journal Of Hospital Pharmacy-Science And Practice, 2018, vol. 25, num. 1, p. 53-56
|Appears in Collections:
|Articles publicats en revistes (Medicina)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.